Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 2
  1. MP. Oral MP is the best therapy choice for this patient. Colchicine alone is inferior to MP, and adding colchicine to MP does not improve efficacy.2 Although hematologic improvement (ie, reduction in the monoclonal protein level) almost never results in immediate improvement in organ dysfunction caused by prior amyloid deposition, patients who have a sustained hematologic response are more likely to eventually have organ function improvement. VBMCP and other combination regimens do not improve response rates significantly but do add toxicity. Thalidomide is poorly tolerated at high doses because it can cause progressive edema, cognitive difficulties, and constipation as well as aggravate preexisting peripheral neuropathy.3

    2. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.

    3.  Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-61.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj